As a first approach, we addressed whether treatment with non-toxic, low doses of IFN-γ + TNF-α could have immunomodulatory effects on BC cells and thus modulate their susceptibility to NK cell-mediated recognition and killing. The gene discussed is TNF; the disease is breast cancer.